Welcome to the Stocktwits Top 25 Newsletter this week!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

Bearish 🐻 | Bullish 🐮 | It’s Complicated 😵‍💫

Here are the Stocktwits Top 25 Lists for this week:

Researching accounts. Building lists. Writing sequences.

There's a better use of your team's time.

Apollo is the AI revenue engine that handles the busywork, so you can stay focused on selling.

Plus, everything you need is in one place:

Stop doing busywork and start building pipeline, faster.

With Apollo — the AI revenue engine powering 4M+ users.

Sign up for free

The board added one FDA catalyst, one spectrum climber, and two very expensive reality checks.

$ATEX ( ▼ 2.47% ) : Anterix, jumped from #23 to #5: This week’s top dawg gained +8.5% as traders rewarded its utility-spectrum progress and support for SpaceX’s FCC proposal. Anterix ended June with $116M in cash and no debt. Risk: Only $9.6M of contracted proceeds is expected through the rest of fiscal 2027.

$ERAS ( ▼ 7.49% ) : Erasca, climbed from #20 to #3: Shares gained +5.6% after the FDA granted Fast Track status to ERAS-0015 for metastatic pancreatic cancer. The designation speeds discussions with regulators, not clinical proof. Risk: The drug remains in Phase 1, with expansion data not expected until the first half of 2027.

$REAX ( ▼ 10.75% ) : Real REMAX Group, new at #1: The +668% weekly jump is mostly mechanical. Real completed its RE/MAX combination Monday, then consolidated shares 10-for-1 before the combined company began trading Tuesday. Risk: Management must integrate 180,000 agents without losing people or promised efficiencies.

$AAOI ( ▼ 6.22% ) : Applied Optoelectronics, fell from #6 to #19: The optical favorite finished the week at -17.4% as traders focused on its $600M at-the-market capacity. That overwhelmed Q2 revenue of $191.9M and a strong production forecast. Risk: New share sales could keep diluting any rebound.

$AEHR ( ▼ 10.67% ) : Aehr Test Systems, held at #7: Holding its rank hid a rough week. Shares finished at -23.7% after management’s Jefferies meetings produced no fresh announcement to support a +301% YTD run. Risk: Fiscal 2027 guidance assumes revenue growth of +160% to +200%. That leaves little room for delays.

Next week’s swing factor: Sept. 1 ISM manufacturing and JOLTS could move rate expectations again, testing every speculative name here.

Want to see some change? Email me, Kevin Travers, with feedback, and follow me on Stocktwits. Send me charts and ideas! Refer a friend for this quarter’s edition of The RIP Forecast 😎

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋